KRAS and neoplasm: In the context of PDAC, one of the most significant pathways through which KRAS drives tumour progression is via the activation of the class 1 phosphoinositide 3-kinase (PI3K) enzymes and their synthesis of the lipid signal PIP3, which is removed by the tumour suppressor PTEN [19,20].